Journal List > Korean J Gastroenterol > v.68(5) > 1007578

TOOLS
Noh, Hong, Han, Park, Lee, Lee, Ko, Lee, and Lee: Eradication Rate by Duration of Third-line Rescue Therapy with Levofloxacin after Helicobacter pylori Treatment Failure in Clinical Practice
Original Article

Korean J Gastroenterol 2016;68(5):260-264.

Published online: 4 October 2016

DOI: https://doi.org/10.4166/kjg.2016.68.5.260

Eradication Rate by Duration of Third-line Rescue Therapy with Levofloxacin after Helicobacter pylori Treatment Failure in Clinical Practice

Hyung Min Noh1, 2, Su Jin Hong1, 2, Jae Pil Han1, 2, Kyung Woo Park1, 2, Yun Nah Lee1, 2, Tae Hee Lee1, 2, Bong Min Ko1, 2, Joon Seong Lee1, 2, Moon Sung Lee1, 2

1Department of Internal Medicine, Soonchunhyang University College of Medicine, Bucheon, Korea

2Digestive Disease Center and Research Institute, Soonchunhyang University College of Medicine, Bucheon, Korea

Correspondence to: Su Jin Hong, Digestive Disease Center and Research Institute, Soonchunhyang University Bucheon Hospital, 170 Jomaru-ro, Wonmi-gu, Bucheon 14584, Korea. Tel: +82-32-621-5087, Fax: +82-32-621-5080, E-mail: sjhong@schmc.ac.kr

Received 29 June 2016       Revised 23 October 2016       Accepted 24 October 2016

Copyright © 2016 Korean Ophthalmological Society

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background/Aims

This study evaluated the eradication rate of levofloxacin-containing rescue therapy by treatment duration in patients in whom previous first- and second-line treatment failed.

Methods

Fifty-five patients with persistent Helicobacter pylori infection after first-line therapy and second-line therapy were studied in a single referral academic center. We compared the eradication rates by the treatment duration of third-line therapy.

Results

Of 55 patients, 12 (21.8%) received rescue therapy for seven days, 24 (43.6%) received rescue therapy for 10 days, and 19 (34.5%) received rescue therapy for 14 days. The eradication rates of therapy with levofloxacin were 65.5% in the 55 enrolled patients and 73.5% in the 49 patients who underwent follow-up testing. In cases where follow-up testing was performed, the eradication rate of 7-day therapy was 58.3%, of 10-day 68.2%, and of 14-day therapy 93.3%. Eradication rate of 14-day therapy was higher than 7-day (p=0.06) and 10-day (p=0.108), but chance could not be ruled out in the difference among groups.

Conclusions

This study showed somewhat increasing of H. pylori eradication rate by extending the duration of levofloxacin-containing rescue therapy to 14 days.

Keywords: Helicobacter pylori, Eradication, Levofloxacin, Rescue therapy

References

1. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut. 2010; 59:1143–1153.
2. Lee JW, Kim N, Kim JM, et al. Prevalence of primary and secondary antimicrobial resistance of Helicobacter pylori in Korea from 2003 through 2012. Helicobacter. 2013; 18:206–214.
3. An B, Moon BS, Kim H, et al. Antibiotic resistance in Helicobacter pylori strains and its effect on H. pylori eradication rates in a single center in Korea. Ann Lab Med. 2013; 33:415–419.
4. Yoon KH, Park SW, Lee SW, Kim BJ, Kim JG. Clarithromycin-based standard triple therapy can still be effective for Helicobacter pylori eradication in some parts of the Korea. J Korean Med Sci. 2014; 29:1240–1246.
5. Malfertheiner P, Megraud F, O'Morain CA, et al. Management of Helicobacter pylori infection–the Maastricht IV/Florence Consensus Report. Gut. 2012; 61:646–664.
6. Kim SG, Jung HK, Lee HL, et al. Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition. J Gastroenterol Hepatol. 2014; 29:1371–1386.
7. Papastergiou V, Georgopoulos SD, Karatapanis S. Current and future insights in H. pylori eradication regimens: the need of tailoring therapy. Curr Pharm Des. 2014; 20:4521–4532.
8. Miehlke S, Krasz S, Schneider-Brachert W, et al. Randomized trial on 14 versus 7 days of esomeprazole, moxifloxacin, and amoxicillin for second-line or rescue treatment of Helicobacter pylori infection. Helicobacter. 2011; 16:420–426.
9. Chuah SK, Tai WC, Hsu PI, et al. The efficacy of second-line an-ti-Helicobacter pylori therapy using an extended 14-day levofloxacin/amoxicillin/proton-pump inhibitor treatment-a pilot study. Helicobacter. 2012; 17:374–381.
10. Murakami K, Furuta T, Ando T, et al. Multi-center randomized controlled study to establish the standard third-line regimen for Helicobacter pylori eradication in Japan. J Gastroenterol. 2013; 48:1128–1135.
11. Tai WC, Lee CH, Chiou SS, et al. The clinical and bacteriological factors for optimal levofloxacin-containing triple therapy in second-line Helicobacter pylori eradication. PLoS One. 2014; 9:e105822.
12. Asaka M, Kato M, Takahashi S, et al. Guidelines for the management of Helicobacter pylori infection in Japan:2009 revised edition. Helicobacter. 2010; 15:1–20.
13. Hwang TJ, Kim N, Kim HB, et al. Change in antibiotic resistance of Helicobacter pylori strains and the effect of A2143G point mutation of 23S rRNA on the eradication of H. pylori in a single center of Korea. J Clin Gastroenterol. 2010; 44:536–543.
14. Chuah SK, Tsay FW, Hsu PI, Wu DC. A new look at anti-Helicobacter pylori therapy. World J Gastroenterol. 2011; 17:3971–3975.
15. Gao W, Cheng H, Hu F, et al. The evolution of Helicobacter pylori antibiotics resistance over 10 years in Beijing, China. Helicobacter. 2010; 15:460–466.
16. Kostamo P, Veijola L, Oksanen A, Sarna S, Rautelin H. Recent trends in primary antimicrobial resistance of Helicobacter pylori in Finland. Int J Antimicrob Agents. 2011; 37:22–25.
17. Fock KM, Katelaris P, Sugano K, et al. Second Asia-Pacific consensus guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol. 2009; 24:1587–1600.
18. Chuah SK, Hsu PI, Chang KC, et al. Randomized comparison of two non-bismuth-containing second-line rescue therapies for Helicobacter pylori. Helicobacter. 2012; 17:216–223.
19. Kim JY, Kim NY, Kim SJ, et al. Regional difference of antibiotic resistance of Helicobacter pylori strains in Korea. Korean J Gastroenterol. 2011; 57:221–229.
20. Gisbert JP, Romano M, Gravina AG, et al. Helicobacter pylori second-line rescue therapy with levofloxacin- and bismuth-containing quadruple therapy, after failure of standard triple or non-bismuth quadruple treatments. Aliment Pharmacol Ther. 2015; 41:768–775.
21. Jeong MH, Chung JW, Lee SJ, et al. Comparison of rifabutin- and levofloxacin-based third-line rescue therapies for Helicobacter pylori. Korean J Gastroenterol. 2012; 59:401–406.
22. Zullo A, Hassan C, De Francesco V, et al. A third-line levofloxacin-based rescue therapy for Helicobacter pylori eradication. Dig Liver Dis. 2003; 35:232–236.
23. Gisbert JP. "Rescue" regimens after Helicobacter pylori treatment failure. World J Gastroenterol. 2008; 14:5385–5402.
24. Li Y, Huang X, Yao L, Shi R, Zhang G. Advantages of Moxifloxacin and Levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis. Wien Klin Wochenschr. 2010; 122:413–422.
25. Hirata Y, Ohmae T, Yanai A, et al. Sitafloxacin resistance in Helicobacter pylori isolates and sitafloxacin-based triple therapy as a third-line regimen in Japan. Int J Antimicrob Agents. 2012; 39:352–355.
26. Tai WC, Chiu CH, Liang CM, et al. Ten-day versus 14-day levofloxacin-containing triple therapy for second-line anti-Helicobacter pylori eradication in Taiwan. Gastroenterol Res Pract. 2013; 2013:932478.
27. Gisbert JP, Romano M, Molina-Infante J, et al. Two-week, highdose proton pump inhibitor, moxifloxacin triple Helicobacter pylori therapy after failure of standard triple or non-bismuth quadruple treatments. Dig Liver Dis. 2015; 47:108–113.
28. Kim JM, Kim JS, Kim N, Jung HC, Song IS. Distribution of fluoroquinolone MICs in Helicobacter pylori strains from Korean patients. J Antimicrob Chemother. 2005; 56:965–967.
29. Kim JM. Antibiotic resistance of Helicobacter pylori isolated from Korean patients. Korean J Gastroenterol. 2006; 47:337–349.
30. Kang MS, Park DI, Yun JW, et al. Levofloxacin-azithromycin combined triple therapy for Helicobacter pylori eradication. Korean J Gastroenterol. 2006; 47:30–36.
31. Lee JH, Hong SP, Kwon CI, et al. The efficacy of levofloxacin based triple therapy for Helicobacter pylori eradication. Korean J Gastroenterol. 2006; 48:19–24.
32. Jung HS, Shim KN, Baik SJ, et al. Efficacy of levofloxacin-based triple therapy as second-line Helicobacter pylori eradication. Korean J Gastroenterol. 2008; 51:285–290.
33. Gatta L, Zullo A, Perna F, et al. A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses. Aliment Pharmacol Ther. 2005; 22:45–49.
crossref
34. Gisbert JP, Morena F. Systematic review and metaanalysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther. 2006; 23:35–44.
35. Gisbert JP, Castro-Fernández M, Bermejo F, et al. Third-line rescue therapy with levofloxacin after two H. pylori treatment failures. Am J Gastroenterol. 2006; 101:243–247.
36. Gisbert JP, Gisbert JL, Marcos S, Moreno-Otero R, Pajares JM. Third-line rescue therapy with levofloxacin is more effective than rifabutin rescue regimen after two Helicobacter pylori treatment failures. Aliment Pharmacol Ther. 2006; 24:1469–1474.
37. Gisbert JP, Pérez-Aisa A, Bermejo F, et al. Second-line therapy with levofloxacin after failure of treatment to eradicate Helicobacter pylori infection: time trends in a Spanish Multicenter Study of 1000 patients. J Clin Gastroenterol. 2013; 47:130–135.
38. Chuah SK, Tai WC, Lee CH, Liang CM, Hu TH. Quinolone-containing therapies in the eradication of Helicobacter pylori. Biomed Res Int. 2014; 2014:151543.
39. Robicsek A, Jacoby GA, Hooper DC. The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect Dis. 2006; 6:629–640.
crossref
40. Hung KH, Sheu BS, Chang WL, Wu HM, Liu CC, Wu JJ. Prevalence of primary fluoroquinolone resistance among clinical isolates of Helicobacter pylori at a University Hospital in Southern Taiwan. Helicobacter. 2009; 14:61–65.
41. Su P, Li Y, Li H, et al. Antibiotic resistance of Helicobacter pylori isolated in the Southeast Coastal Region of China. Helicobacter. 2013; 18:274–279.
42. Devasia RA, Blackman A, Gebretsadik T, et al. Fluoroquinolone resistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure. Am J Respir Crit Care Med. 2009; 180:365–370.

Fig. 1.
Study flowchart.
kjg-68-260f1.tif
Table 1.
Baseline Characteristics of Enrolled Patients
Characteristic Total (n=55) 7-day group (n=12) 10-day group (n=24) 14-day group (n=19) p-value
Age (yr) 57.4±12.1 54.8±13.7 59.3±12.4 56.7±10.9 NS*
Sex, male/female 27 (49.1)/28 (50.9) 5 (41.7)/7 (58.3) 12 (50.0)/12 (50.0) 10 (52.6)/9 (47.4) 0.884
Disease         0.231
 Gastric ulcer 38 (69.1) 7 (58.3) 19 (79.2) 12 (63.2)  
 Duodenal ulcer 16 (29.1) 4 (33.3) 5 (20.8) 7 (36.8)  
 Helicobacter pylori gastritis 1 (1.8) 1 (8.3) 0 (0) 0 (0)  
Follow-up 49 (89.1) 12 (100) 22 (91.7) 15 (78.9) 0.151

Values are presented as mean±SD or n (%).

* No significant differences between groups (p＞0.05).

Table 2.
Eradication Rate according to Duration of Third-line Rescue Treatment
Treatment duration Eradication rate
Enrolled patients (total, n=55) Subgroup (follow-up, n=49)
7-day group 58.3 (0.286–0.835) 58.3 (0.286–0.835)
10-day group 62.5 (0.408–0.805) 68.2 (0.451–0.853)
14-day group 73.7 (0.486–0.899)† 93.3 (0.660–0.997)‡
Total 65.5 (0.513–0.774) 73.5 (0.587–0.846)

Values are presented as % (95% CI).

† p=0.447 compared with 7-day group, 7-day group.

‡ p=0.06 compared with

TOOLS
Similar articles